Locations:
Min Investment:
Max Investment:
Target Investment:
2015
2015
Abingworth invests in private and public life sciences companies. We are currently investing $1.1b in funds.
2023
Iambic Therapeutics combines physics and AI to create a differentiated drug discovery platform to quickly and efficiently create potentially best-in-class molecules.
2020
2020
2020
Orbus is a phase 3 oncology company. Eflornithine is a novel cytostatic agent that inhibits tumor growth by preventing cell division and proliferation which Orbus Therapeutics is developing for the treatment of patients with anaplastic astrocytoma (AA), or Grade 3 glioma, a rare and deadly form of brain cancer. Eflornithine irreversibly blocks ornithine decarboxylase (ODC), a key enzyme associated with various types of cancer.
2020
SFJ Pharmaceuticals® is a global specialty pharmaceutical company with an innovative pharmaceutical co-development model that provides an advantageous alternative to traditional pharma partnerships. SFJ Pharmaceuticals®’s unique partnering approach provides experienced clinical and medical professionals, clinical development resources and operational oversight and execution to accelerate late-phase drug development candidates across multiple indications and therapeutic areas. The result is pipeline acceleration for our partners.
2019
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
2009 - 2024
2009 - 2024
2015 - 2022
2015 - 2022
Vaxcyte is developing best-in-class vaccines for human health.
2020 - 2022
2020 - 2022
Our mission is to improve medical treatment for patients with immunologic and inflammatory diseases. Our lead program is atacicept for IgAN currently in Phase 2 clinical development.
2020 - 2022
2020 - 2022